Nitrosoglutathione generating nitric oxide nanoparticles as an improved strategy for combating Pseudomonas aeruginosa - Infected wounds

Journal of Drugs in Dermatology

Volumn 11, Issue 12, 2012, Pages 1471-1477

  Chouake, Jason ^a   Schairer, David ^a   Kutner, Allison ^a   Sanchez, David A ^b   Makdisi, Joy ^a   Blecher Paz, Karin ^a   Nacharaju, Parimala ^b   Tuckman Vernon, Chaim ^b   Gialanella, Phil ^a   Friedman, Joel M ^b   Nosanchuk, Joshua D ^a,b   Friedman, Adam J ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; NANOPARTICLE; NITRIC OXIDE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; S NITROSOGLUTATHIONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PSEUDOMONAS INFECTION; WOUND CLOSURE; WOUND INFECTION;

ANIMALS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; NITRIC OXIDE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; S-NITROSOGLUTATHIONE; SKIN; SURGICAL WOUND INFECTION; VASODILATOR AGENTS; WOUND HEALING;

EID: 84871089783     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36 Suppl 2:S50-S54.
2. Yoshida J, Akagi K, Ishimaru T, et al. Drug resistance of Pseudomonas aeruginosa in four community hospitals: influence of antimicrobial use density [in Japanese]. Jpn J Antibiot. 2011;64(4):247-253.
3. Park YS, Lee H, Chin BS, et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J Hosp Infect . 2011;79(1):54-58.
4. Wu DC, Chan WW, Metelitsa AI, Fiorillo L, Lin AN. Pseudomonas skin infection: clinical features, epidemiology, and management. Am J Clin Dermatol. 2011;12(3):157-169.
5. Siebenhaar F, Syska W, Weller K, et al. Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol. 2007;170(6):1910-1916. (Pubitemid 47339265)
6. Higaki S, Kitagawa T, Kagoura M, Morohashi M, Yamagishi T. Characteristics of Pseudomonas aeruginosa isolated from skin infections. Drugs Exp Clin Res. 2001;27(4):121-126. (Pubitemid 34051595)
7. Friedman A, Blecher K, Sanchez D, et al. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence. 2011;2(3):217-221.
8. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs . 2009;69(14):1879-1901.
9. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13(47).
10. Dou Y, Zhang X, Zhang Q, Shi Y. Analysis of the drug-resistance of Pseudomonas aeruginosa and the use of antibiotics in burn wards [in Chinese]. Zhonghua Shao Shang Za Zhi. 2011;27(2):109-113.
11. Haddadin RN, Saleh SA, Mahmoud RA, Shehabi AA. Multiple drug resistance and strength of attachment to surfaces in Pseudomonas aeruginosa isolates. Lett Appl Microbiol. 2010;51(1):48-53.
12. Hu XH, Xu XM, Mi ZH, Fan YF, Feng WY. Relationship between drug resistance of Pseudomonas aeruginosa isolated from burn wounds and its mobile genetic elements [in Chinese]. Zhonghua Shao Shang Za Zhi. 2009;25(2):103-105.
13. Yu J, Sun YX, Zhang CH. Drug resistance of imipenem-resistant Pseudomonas aeruginosa of lower respiratory tract in pulmonary heart disease of coal worker's pneumoconiosis [in Chinese]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2008;26(4):236-237.
14. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43-48. (Pubitemid 43042900)
15. Hocquet D, Berthelot P, Roussel-Delvallez M, et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother. 2007;51(10):3531-3536.
16. Fang FC, Vazquez-Torres A. Nitric oxide production by human macrophages: there's NO doubt about it. Am J Physiol Lung Cell Mol Physiol. 2002;282(5):L941-L943.
17. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest. 1997;99(12):2818- 2825. (Pubitemid 27278655)
18. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med. 2009;15(9):391-404.
19. Han G, Zippin JH, Friedman A. From bench to bedside: the therapeutic potential of nitric oxide in dermatology. J Drugs Dermatol. 2009;8(6):586-594.
20. Potera C. Nanoparticles deliver nitric oxide locally. Genet Eng Biotechnol News. 2010;30(14):12-13.
21. Akaike T, Okamoto T, Zaki MH, Fujii S, Sawa T. New paradigm of host defense against intracellular pathogens by nitric oxide [in Japanese]. Nihon Hansenbyo Gakkai Zasshi. 2009;78(1):41-47.
22. Coban AY. Antimicrobial effect of nitric oxide [in Turkish]. Salud I Ciencia. 2008;16(1):1340-1341.
23. Vazquez-Torres A, Stevanin T, Jones-Carson J, Castor M, Read RC, Fang FC. Analysis of nitric oxide-dependent antimicrobial actions in macrophages and mice. Methods Enzymol. 2008;437:521-538.
24. De Groote MA, Fang FC. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis. 1995;21 Suppl 2:S162-S165.
25. Mihu MR, Sandkovsky U, Han G, Friedman JM, Nosanchuk JD, Martinez LR. The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence . 2010;1(2):62-67.
26. Martinez LR, Han G, Chacko M, et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J Invest Dermatol. 2009;129(10):2463-2469.
27. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One. 2009;4(11):e7804.
28. Friedman AJ, Blecher K, Schairer D, et al. Improved antimicrobial efficacy with nitric oxide releasing nanoparticle generated S- nitrosoglutathione. Nitric Oxide. 2011;25(4):381-386.
29. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci. 1995;16(1):18-22.
30. Friedman AJ, Han G, Navati MS, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19(1):12-20.
31. Richie JP Jr, Skowronski L, Abraham P, Leutzinger Y. Blood glutathione concentrations in a large-scale human study. Clin Chem. 1996;42(1):64-70. (Pubitemid 26030383)
32. Han G, Friedman AJ, Friedman JM. Nitric oxide releasing nanoparticle synthesis and characterization. Methods Mol Biol. 2011;704:187-195.
33. Major TA, Panmanee W, Mortensen JE, Gray LD, Hoglen N, Hassett DJ. Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions. Antimicrob Agents Chemother. 2010;54(11):4671-4677.
34. Barraud N, Schleheck D, Klebensberger J, et al. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol. 2009;191(23):7333- 7342.
35. Nablo BJ, Rothrock AR, Schoenfisch MH. Nitric oxide-releasing sol-gels as antibacterial coatings for orthopedic implants. Biomaterials. 2005;26(8):917-924. (Pubitemid 39194963)
36. Darling KE, Evans TJ. Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis. Infect Immun. 2003;71(5):2341-2349. (Pubitemid 36519844)
37. Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012;3(3):271-279.
38. Privett BJ, Broadnax AD, Bauman SJ, Riccio DA, Schoenfisch MH. Examination of bacterial resistance to exogenous nitric oxide. Nitric Oxide. 2012;26(3):169-173.
39. Schairer D, Martinez L, Blecher K, et al. Nitric oxide nanoparticles: pre-clinical utility as a therapeutic for intramuscular abscesses. Virulence. 2012;3(1):62-67.
40. Macherla C, Sanchez DA, Ahmadi MS, et al. Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections. Front Microbiol. 2012;3:193.
41. Moore CM, Nakano MM, Wang T, Ye RW, Helmann JD. Response of Bacillus subtilis to nitric oxide and the nitrosating agent sodium nitroprusside. J Bacteriol. 2004;186(14):4655-4664. (Pubitemid 38891029)
42. Poole RK. Nitric oxide and nitrosative stress tolerance in bacteria. Biochem Soc Trans. 2005;33(Pt 1):176-180. (Pubitemid 40313794)
43. MacMicking J, Xie QW, Nathan C. Nitric odixe and macrophate function. Annu Rev Immunol. 1997;15:323-350.
44. Abouhamad WN, Manson M, Gibson MM, Higgins CF. Peptide transport and chemotaxis in Escherichia coli and Salmonella typhimurium: characterization of the dipeptide permease (Dpp) and the dipeptide-binding protein. Mol Microbiol. 1991;5(5):1035-1047. (Pubitemid 21896129)
45. De Groote MA, Ochsner UA, Shiloh MU, et al. Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase. Proc Natl Acad Sci U S A. 1997;94(25):13997-14001. (Pubitemid 28009698)
46. De Groote MA, Testerman T, Xu Y, Stauffer G, Fang FC. Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium. Science. 1996;272(5260):414-417.
47. De Groote MA, Granger D, Xu Y, Campbell G, Prince R, Fang FC. Genetic and redox determinants of nitric oxide cytotoxicity in a Salmonella typhimurium model. Proc Natl Acad Sci U S A. 1995;92(14):6399-6403.
48. Morris SL, Hansen JN. Inhibition of Bacillus cereus spore outgrowth by covalent modification of a sulfhydryl group by nitrosothiol and iodoacetate. J Bacteriol. 1981;148(2):465-471. (Pubitemid 12218747)
49. Broughton G 2nd, Janis JE, Attinger CE. The basic science of wound healing. Plast Reconstr Surg. 2006;117(7 Suppl):12S-34S. (Pubitemid 44317769)
50. Schäffer MR, Tantry U, Thornton FJ, Barbul A. Inhibition of nitric oxide synthesis in wounds: pharmacology and effect on accumulation of collagen in wounds in mice. Eur J Surg. 1999;165(3):262-267. (Pubitemid 29374457)
51. Shukla A, Rasik AM, Shankar R. Nitric oxide inhibits wounds collagen synthesis. Mol Cell Biochem. 1999;200(1-2):27-33. (Pubitemid 29490651)
52. Han G, Nguyen LN, Macherla C, et al. Nitric oxide-releasing nanoparticles accelerate wound healing by promoting fibroblast migration and collagen deposition. Am J Pathol. 2012;180(4):1465-1473.
53. Blecher K, Martinez LR, Tuckman-Vernon C, et al. Nitric oxide-releasing nanoparticles accelerate wound healing in NOD-SCID mice. Nanomedicine. 2012;8(8):1364-1371.
54. Georgii JL, Amadeu TP, Seabra AB, de Oliveira MG, Monte-Alto-Costa A. Topical S-nitrosoglutathione-releasing hydrogel improves healing of rat ischaemic wounds. J Tissue Eng Regen Med. 2011;5(8):612-619.